All companies › RPRX

RPRX · Royalty Pharma plc

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells4
Research cases0
Last filing2026-10-05

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-22 — Hite Christopher · sold 3,927 @ $58.93 2026-09-22 — Hite Christopher · sold 96,073 @ $58.51 2026-09-28 — Urist Marshall · sold 4,126 @ $57.88 2026-10-05 — Urist Marshall · sold 4,126 @ $57.10
2026-09-222026-10-05

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Hite Christopher EVP & Chairman, Partnering
Urist Marshall EVP, Research & Investments
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $RPRX is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-10-05', 'insider_name': 'Urist Marshall', 'insider_title': 'EVP, Research & Investments', 'transaction_type': 'Open-market sell', 'shares': 4126.0, 'price': 57.1, 'value': 235594.6, 'is_buy': False}, {'transaction_date': '2026-09-28', 'insider_name': 'Urist Marshall', 'insider_title': 'EVP, Research & Investments', 'transaction_type': 'Open-market sell', 'shares': 4126.0, 'price': 57.88, 'value': 238812.88, 'is_buy': False}, {'transaction_date': '2026-09-22', 'insider_name': 'Hite Christopher', 'insider_title': 'EVP & Chairman, Partnering', 'transaction_type': 'Open-market sell', 'shares': 3927.0, 'price': 58.93, 'value': 231418.11, 'is_buy': False}, {'transaction_date': '2026-09-22', 'insider_name': 'Hite Christopher', 'insider_title': 'EVP & Chairman, Partnering', 'transaction_type': 'Open-market sell', 'shares': 96073.0, 'price': 58.51, 'value': 5621231.23, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for RPRX today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.